Related Experiment Videos
Ifosfamide in non-small-cell lung cancer
1Medical Oncology Service, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. rrosell@ns.hugtip.scs.es
Summary
New ifosfamide combinations show promise, potentially improving objective response rates and delaying disease progression compared to older regimens like Cullen
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Ifosfamide is a key chemotherapy agent used in various combinations.
- Established regimens like the ifosfamide-cisplatin-mitomycin (Cullen's MIC) regimen have been widely used.
- Recent phase III trials indicate newer combinations may offer improved efficacy.
Purpose of the Study:
- To review and analyze various ifosfamide-based doublets and triplets.
- To compare the efficacy of novel ifosfamide combinations against traditional regimens.
- To highlight promising new chemotherapy combinations in oncology.
Main Methods:
- Review of existing literature and clinical trial data.
- Analysis of objective response rates (ORR) and time to disease progression (TTP).
- Comparison of ifosfamide doublets and triplets, including novel combinations.
Main Results:
- Newer ifosfamide combinations are emerging as effective alternatives.
- Ifosfamide-vinorelbine and ifosfamide-gemcitabine-cisplatin show particular promise.
- These novel combinations may offer advantages over older chemotherapy regimens.
Conclusions:
- Ifosfamide remains a valuable chemotherapeutic agent.
- Novel ifosfamide combinations demonstrate potential for enhanced anti-cancer activity.
- Further investigation into these promising regimens is warranted.